title: Human monocyte responses to lipopolysaccharide and 9-cis retinoic acid after laparoscopic surgery for colon cancer.
abstract: Surgery, even modern minimal invasive laparoscopic surgery, induces an initial inflammatory and acute phase response which is followed by a period of immunosuppression rendering surgical patients more susceptible to infection. Here, we aimed to study changes in monocyte inflammatory responses and inflammatory modulation mechanisms following laparoscopic colorectal surgery for colon cancer. Blood samples were collected from 19 colon cancer patients before, directly after and daily for 3 days following surgery. Blood cells were exposed ex vivo to bacterial lipopolysaccharide (LPS) or the inflammatory modulator 9-cis retinoic acid (9cisRA). In blood samples taken prior to surgery, we found significant pro-inflammatory responses to LPS, indicating classical monocyte activation. Directly after surgery, LPS induced significantly less early pro-inflammatory cytokines and monocyte/granulocyte-attracting chemokines. The LPS-mediated release of interleukin (IL)-1β was still significantly attenuated 3 days after surgery. In patient monocytes collected after surgery, we found increased levels of suppressors of cytokine signaling (SOCS)1 and SOCS3 mRNA, reported to be associated with polarization towards resolving macrophages. The retinoic acid isomer 9cisRA, reported to attenuate LPS-mediated inflammatory responses and alter chemokine responses in cultured monocytes, had a similar effect in patient blood. Three days after surgery, 9cisRA still attenuated pro-inflammatory responses, but the induction of monocyte chemoattractive protein (MCP)-1/CCL2 mRNA in monocytes was reduced. This study indicates changes in monocyte responses that last for at least 3 days after laparoscopic surgery.
authors.affiliation: Institute for Surgical Research, Oslo University Hospital Rikshospitalet HF, Oslo, Norway.
authors.forename: Ingrid B M
authors.initials: IB
authors.lastname: Kolseth
authors.forename: Dag T
authors.initials: DT
authors.lastname: Førland
authors.forename: Petter K
authors.initials: PK
authors.lastname: Risøe
authors.forename: Signe
authors.initials: S
authors.lastname: Flood-Kjeldsen
authors.forename: Joanna
authors.initials: J
authors.lastname: Ågren
authors.forename: Janne E
authors.initials: JE
authors.lastname: Reseland
authors.forename: Staale P
authors.initials: SP
authors.lastname: Lyngstadaas
authors.forename: Egil
authors.initials: E
authors.lastname: Johnson
authors.forename: Maria K
authors.initials: MK
authors.lastname: Dahle
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077556:Alitretinoin; D002097:C-Reactive Protein / Q000378:metabolism; D003110:Colonic Neoplasms / Q000097:blood / Q000150:complications / Q000473:pathology* / Q000601:surgery*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000150:complications / Q000473:pathology; D018836:Inflammation Mediators / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D010535:Laparoscopy; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D000071222:Suppressor of Cytokine Signaling 1 Protein; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins / Q000235:genetics / Q000378:metabolism; D016896:Treatment Outcome; D014212:Tretinoin / Q000494:pharmacology*
chemical_list: D018836:Inflammation Mediators; D015850:Interleukin-6; D008070:Lipopolysaccharides; D012333:RNA, Messenger; C108944:SOCS1 protein, human; C106644:SOCS3 protein, human; D000071222:Suppressor of Cytokine Signaling 1 Protein; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins; D000077556:Alitretinoin; D014212:Tretinoin; D002097:C-Reactive Protein